Our results provided evidence for the NIH and St.Gallen International Conference of Breast Cancer's suggestion that ER+ and/or PR+ breast cancer patients should receive post-operative adjuvant ET regardless of age, menstruation status, tumor size, and regional lymphatic metastasis status[25].Specifically, all hormone receptor-positive patients should undergo ET before and after surgery). The gene discussed is ESR1; the disease is neoplasm.